AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Pubmed Ncbi Nlm Nih

Published November 12, 2026

Convergent and Divergent Mechanisms of Ketamine and Psychedelics - PubMed

Read the full story at Pubmed Ncbi Nlm Nih

Rapid-acting antidepressants have challenged the long-standing view that therapeutic improvement in major depressive disorder requires chronic.

Post on X

Share this story

Surfaced by 2 Google Alerts

Psychedelics
Ketamine